

Diagnostics

Kit for predicting the response to treatment with MSCs in patients with inflammatory diseases

A research group from Andalusian Public Health System has developed a kit for predicting the response to treatment with Mesenchymal Stem Cells (MSCs) in patients with inflammatory diseases.

Oficina de
**TRANSFERENCIA
DE TECNOLOGÍA**
Sistema Sanitario Público de Andalucía



Description

The treatment of inflammatory diseases with MSCs is often associated with the development of thrombosis. Consequently, there is currently a need to provide a safety test in order to determine the risk of suffering a thrombotic event after treatment.

The research group has developed a prognosis kit based on measurement of the level expression of two proteins to predict a thrombotic event associated with treatment with MSCs in patients with inflammatory diseases.

The researchers have conducted a clinical study to evaluate the safety and feasibility of intra-arterial administration of autologous adipose derived mesenchymal stem cells in 36 diabetic patients with critical limb ischemia (CLI).



Intellectual Property

The technology is protected by a european patent application.



Aims

The research group is looking for a collaboration agreement for further development or a licence agreement.



Advantages

- This test allows allocating the human subject in one of two groups, wherein group 1 comprise subjects with low risk of having a thrombotic event after treatment, and wherein group 2 represents the remaining subjects.
- The kit enables determine the best treatment for each
- patient.



Classification

Area: Diagnostic
Technology: Cell therapy
Pathology: Autoimmune and inflammation